Pharmacothérapie pratique à l'officine : l'essentiel, 2004. ,
Psychopharmacologie essentielle : Bases neuroscientifiques et applications pratiques, 2010. ,
La schizophrénie de l'adulte : Des causes aux traitements, 2006. ,
DSM-IV-TR Manuel diagnostique et statistique des troubles mentaux : Texte révisié, 2003. ,
Fifty years chlorpromazine: a historical perspective, Neuropsychiatr. Dis. Treat, vol.3, pp.495-500, 2007. ,
Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)], Ann. Méd.-Psychol, vol.110, pp.112-117, 1952. ,
Effect of Chlorpromazine or Haloperidol on Formation of 3-Methoxytyramine and Normetanephrine in Mouse Brain, Acta Pharmacologica et Toxicologica, vol.8, issue.no. 7, pp.140-144, 1963. ,
DOI : 10.1111/j.1600-0773.1963.tb01730.x
Clozapine for the Treatment-Resistant Schizophrenic, Archives of General Psychiatry, vol.45, issue.9, pp.789-796, 1988. ,
DOI : 10.1001/archpsyc.1988.01800330013001
Psychopharmacological and clinical classification of different neuroleptic drugs. General therapeutic indications in psychoses, Presse Médicale, pp.1509-1511, 1960. ,
Clinical classification of neuroleptics, with special reference to their antimanic, antiautistic, and ataraxic properties, Comprehensive Psychiatry, vol.13, issue.2, pp.123-131, 1972. ,
DOI : 10.1016/0010-440X(72)90017-X
Dose equivalence of the anti-psychotic drugs, J. Psychiatr. Res, vol.11, pp.65-69, 1974. ,
Psychiatrie de l'enfant, de l'adolescent et de l'adulte, 2009. ,
Propranolol Treatment for Neuroleptic-Induced Akathisia, The Primary Care Companion to The Journal of Clinical Psychiatry, vol.07, issue.04, pp.202-203, 2005. ,
DOI : 10.4088/PCC.v07n0412b
Managing Antipsychotic-Induced Acute and Chronic Akathisia, Drug Safety, vol.28, issue.6, pp.73-81, 2000. ,
DOI : 10.2165/00002018-200022010-00006
FMPMC-PS -Pharmacologie -DCEM1, XENAZINE® (tetrabenazine) Move of Action ,
Neuroleptic-induced hyperprolactinemia, Schizophrenia Research, vol.35, pp.75-86, 1999. ,
DOI : 10.1016/S0920-9964(98)00159-5
at <http://facmed.univ- rennes1.fr ,
Antipsychotic-Induced Hyponatraemia, Drug Safety, vol.131, issue.10, pp.101-114, 2010. ,
DOI : 10.2165/11319070-000000000-00000
at <http://www.gyneweb.fr/Sources/gyngene/gynendoc/galact.html> 41. Nos derniers articles > La thyroide : signes et causes de mauvais fonctionnements ,
Thyroid Adverse Effects of Psychotropic Drugs, Clinical Neuropharmacology, vol.34, issue.6, pp.248-255, 2011. ,
DOI : 10.1097/WNF.0b013e31823429a7
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis, BMJ, vol.321, issue.7273, pp.1371-1376, 2000. ,
DOI : 10.1136/bmj.321.7273.1371
French version of American Physician's Desk Reference (PDR)) (Dictionnaire Vidal (French & European Publishing)) (French Edition), 2011. ,
Clinical and theoretical implications of 5- HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia, Am. J. Psychiatry, vol.156, pp.286-293, 1999. ,
Antipsychotic Drugs and Their Side-Effects, 1993. ,
Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials, CMAJ Can. Med. Assoc. J, vol.170, p.1395, 2004. ,
Practice guideline for the treatment of patients with schizophrenia, second edition, Am. J. Psychiatry, vol.161, pp.1-56, 2004. ,
The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.34, issue.6, 2010. ,
DOI : 10.1016/j.pnpbp.2010.04.003
Metabolic syndrome and mental illness, 2007. ,
Metabolic Syndrome Associated with Schizophrenia and Atypical Antipsychotics, Current Diabetes Reports, vol.58, issue.Suppl 1, pp.209-216, 2010. ,
DOI : 10.1007/s11892-010-0112-8
Weight Gain and Metabolic Syndrome Among Young Patients on Antipsychotic Medication: What do we Know and Where do we go?, Australasian Psychiatry, vol.66, issue.3, 2011. ,
DOI : 10.3109/10398562.2010.539609
Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice, European Psychiatry, vol.26, issue.3, pp.144-158, 2011. ,
DOI : 10.1016/j.eurpsy.2010.09.011
Metabolic Syndrome in Severe Mental Disorders, Metabolic Syndrome and Related Disorders, vol.9, issue.2, pp.91-98, 2011. ,
DOI : 10.1089/met.2010.0053
obé sité abdominale, une maladie mé tabolique, 2007. ,
enquête épidémiologique de référence sur l'évolution de l'obésité et du surpoids en France ,
Surpoids et obésité de l'adulte : prise en charge médicale de premier recours. at <http://www.has-sante.fr/portail/jcms/c_964938/fr/surpoids-et- obesite-de-l-adulte-prise-en-charge-medicale-de-premier-recours> ,
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial, Archives of General Psychiatry, vol.64, issue.6, pp.633-647, 2007. ,
DOI : 10.1001/archpsyc.64.6.633
Metabolic issues and cardiovascular disease in patients with psychiatric disorders, The American Journal of Medicine Supplements, vol.118, issue.2, pp.15-22, 2005. ,
DOI : 10.1016/j.amjmed.2005.01.046
Diabetes mellitus in schizophrenic patients, Comprehensive Psychiatry, vol.37, issue.1, pp.68-73, 1996. ,
DOI : 10.1016/S0010-440X(96)90054-1
FAMILY HISTORY OF TYPE 2 DIABETES IN SCHIZOPHRENIC PATIENTS, The Lancet, vol.333, issue.8636, p.495, 1989. ,
DOI : 10.1016/S0140-6736(89)91392-5
Schizophrenia, antipsychotics and diabetes: Genetic aspects, European Psychiatry, vol.20, pp.335-339, 2005. ,
DOI : 10.1016/S0924-9338(05)80187-7
Stress and the genesis of diabetes mellitus in schizophrenia, The British Journal of Psychiatry, vol.184, issue.47, pp.72-75, 2004. ,
DOI : 10.1192/bjp.184.47.s72
Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions, Ann. Clin. Psychiatry Off. J. Am. Acad. Clin. Psychiatr, vol.23, pp.131-140, 2011. ,
Diab??te et antipsychotiques de seconde g??n??ration, Annales d'Endocrinologie, vol.70, issue.4, pp.202-210, 2009. ,
DOI : 10.1016/j.ando.2009.07.003
Dosing the antipsychotic medication olanzapine, J. Clin. Psychiatry, vol.58, pp.45-49, 1997. ,
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia, New England Journal of Medicine, vol.353, issue.12, pp.1209-1223, 2005. ,
DOI : 10.1056/NEJMoa051688
Antipsychotic-induced weight gain: a comprehensive research synthesis, Am. J. Psychiatry, vol.156, pp.1686-1696, 1999. ,
Amisulpride is an ?atypical? antipsychotic associated with low weight gain, Psychopharmacology, vol.173, issue.1-2, pp.112-115, 2004. ,
DOI : 10.1007/s00213-003-1721-6
Safety and tolerability of antipsychotics: focus on amisulpride. Drug Healthc, Patient Saf, vol.2, pp.205-211, 2010. ,
A review of the effect of atypical antipsychotics on weight, Psychoneuroendocrinology, vol.28, pp.83-96, 2003. ,
DOI : 10.1016/S0306-4530(02)00114-2
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia, J. Clin. Psychiatry, vol.65, pp.4-18, 2004. ,
Second-Generation (Atypical) Antipsychotics and Metabolic Effects, CNS Drugs, vol.161, issue.4, pp.1-93, 2005. ,
DOI : 10.2165/00023210-200519001-00001
Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study, American Journal of Psychiatry, vol.157, issue.6, pp.975-981, 2000. ,
DOI : 10.1176/appi.ajp.157.6.975
Adverse Metabolic Effects Associated with Atypical Antipsychotics, Drugs, vol.286, issue.7, pp.701-723, 2004. ,
DOI : 10.2165/00003495-200464070-00003
A Case Series: Evaluation of the Metabolic Safety of Aripiprazole, Schizophrenia Bulletin, vol.33, issue.3, pp.823-830, 2007. ,
DOI : 10.1093/schbul/sbl037
Risperidone-Associated Diabetes Mellitus: A Pharmacovigilance Study, Pharmacotherapy, vol.60, issue.23, pp.735-744, 2003. ,
DOI : 10.1016/S0304-3940(99)00712-0
Clozapine-associated diabetes, The American Journal of Medicine, vol.111, issue.9, pp.716-723, 2001. ,
DOI : 10.1016/S0002-9343(01)01000-2
Olanzapine-Associated Diabetes Mellitus, Pharmacotherapy, vol.46, issue.7, pp.841-852, 2002. ,
DOI : 10.4088/JCP.v61n1111b
A Survey of Reports of Quetiapine-Associated Hyperglycemia and Diabetes Mellitus, The Journal of Clinical Psychiatry, vol.65, issue.6, pp.857-863, 2004. ,
DOI : 10.4088/JCP.v65n0619
Ketoacidosis as a side-effect of clozapine: a case report, Acta Psychiatrica Scandinavica, vol.151, issue.3, pp.217-218, 1996. ,
DOI : 10.1111/j.1600-0447.1996.tb10635.x
Diabetic ketoacidosis from clozapine and lithium cotreatment, Am. J. Psychiatry, vol.153, pp.737-738, 1996. ,
Current Management Strategies for Coexisting Diabetes Mellitus and Obesity, Drugs, vol.44, issue.12, pp.1165-1184, 2003. ,
DOI : 10.2165/00003495-200363120-00001
A Double Blind, Placebo-Controlled, Randomized Crossover Study of the Acute Metabolic Effects of Olanzapine in Healthy Volunteers, PLoS ONE, vol.35, issue.8, p.22662, 2011. ,
DOI : 10.1371/journal.pone.0022662.s002
The effects of antipsychotic therapy on serum lipids: a comprehensive review, Schizophrenia Research, vol.70, issue.1, pp.1-17, 2004. ,
DOI : 10.1016/j.schres.2004.01.014
Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study, Schizophrenia Research, vol.111, issue.1-3, pp.9-16, 2009. ,
DOI : 10.1016/j.schres.2009.03.025
Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications, Primary Care Diabetes, vol.3, issue.1, pp.5-15, 2009. ,
DOI : 10.1016/j.pcd.2008.10.005
Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis, Psychopharmacol. Bull, vol.42, pp.11-31, 2009. ,
Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population, International Clinical Psychopharmacology, vol.24, issue.4, pp.204-213, 2009. ,
DOI : 10.1097/YIC.0b013e32832d6c18
New-onset type-2 diabetes associated with atypical antipsychotic medications, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.30, issue.5, pp.919-923, 2006. ,
DOI : 10.1016/j.pnpbp.2006.02.007
Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-affective Disorder: Findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study, American Journal of Psychiatry, vol.165, issue.11, pp.1420-1431, 2008. ,
DOI : 10.1176/appi.ajp.2008.08050756
The Association Between HTR2C Gene Polymorphisms and the Metabolic Syndrome in Patients With Schizophrenia, Journal of Clinical Psychopharmacology, vol.27, issue.4, pp.338-343, 2007. ,
DOI : 10.1097/JCP.0b013e3180a76dc0
Weight gain in bipolar disorder: pharmacological treatment as a contributing factor, Acta Psychiatrica Scandinavica, vol.66, issue.1, pp.4-18, 2008. ,
DOI : 10.1034/j.1600-0447.2001.00240.x
Antipsychotic Induced Weight Gain in Schizophrenia: Mechanisms and Management, Australian & New Zealand Journal of Psychiatry, vol.58, issue.5, pp.369-381, 2008. ,
DOI : 10.1176/ajp.2006.163.12.2072
Atypical antipsychotic-induced diabetes mellitus: an update on epidemiology and postulated mechanisms, Internal Medicine Journal, vol.111, issue.7, pp.602-606, 2008. ,
DOI : 10.1111/j.1445-5994.2008.01712.x
Association Between HTR2C and HTR2A Polymorphisms and Metabolic Abnormalities in Patients Treated With Olanzapine or Clozapine, Journal of Clinical Psychopharmacology, vol.29, issue.1, pp.65-68, 2009. ,
DOI : 10.1097/JCP.0b013e31819302c3
Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin, Schizophrenia Research, vol.100, issue.1-3, pp.70-85, 2008. ,
DOI : 10.1016/j.schres.2007.11.026
Effets métaboliques et endocriniens des antipsychotiques atypiques, 2003. ,
Serum leptin levels increase rapidly after initiation of clozapine therapy, Molecular Psychiatry, vol.3, issue.1, pp.76-80, 1998. ,
DOI : 10.1038/sj.mp.4000352
A prospective study of serum ghrelin levels in patients treated with clozapine, Journal of Neural Transmission, vol.50, issue.10, pp.1411-1416, 1996. ,
DOI : 10.1007/s00702-005-0284-6
Pronounced Early Increase in Circulating Leptin Predicts a Lower Weight Gain During Clozapine Treatment, Journal of Clinical Psychopharmacology, vol.22, issue.4, pp.424-426, 2002. ,
DOI : 10.1097/00004714-200208000-00015
Olanzapine-Induced Hyperphagia and Weight Gain Associate with Orexigenic Hypothalamic Neuropeptide Signaling without Concomitant AMPK Phosphorylation, PLoS ONE, vol.117, issue.6, p.20571, 2011. ,
DOI : 10.1371/journal.pone.0020571.t001
Inhibitory Effects of Antipsychotics on Carbachol-Enhanced Insulin Secretion From Perifused Rat Islets: Role of Muscarinic Antagonism in Antipsychotic-Induced Diabetes and Hyperglycemia, Diabetes, vol.54, issue.5, pp.1552-1558, 2005. ,
DOI : 10.2337/diabetes.54.5.1552
Régulation du métabolisme énergétique par l'APMK, Med. Sci, vol.22, 2006. ,
Le journal faxé de l'endocrinologue sur le mécanisme d'action central de la leptine, 2008. ,
Olanzapine-Induced Hyperglycemia: Possible Involvement of Histaminergic, Dopaminergic and Adrenergic Functions in the Central Nervous System, Neuroendocrinology, vol.98, issue.3, 2013. ,
DOI : 10.1159/000356119
Olanzapine induces glucose intolerance through the activation of AMPK in the mouse hypothalamus, European Journal of Pharmacology, vol.718, issue.1-3, 2013. ,
DOI : 10.1016/j.ejphar.2013.08.006
Targeting Intermediary Metabolism in the Hypothalamus as a Mechanism to Regulate Appetite, Pharmacological Reviews, vol.62, issue.2, pp.237-264, 2010. ,
DOI : 10.1124/pr.109.002428
Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase ,
Tome 2: Orientations diagnostiques : les spécificités de l'adolescence, 2013. ,
A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients, BMC Psychiatry, vol.19, issue.6 Suppl, p.28, 2007. ,
DOI : 10.1177/0269881105058380
Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis, British Journal of Clinical Pharmacology, vol.24, issue.3, pp.377-382, 2011. ,
DOI : 10.1111/j.1365-2125.2010.03783.x
appelé aussi diabète non insulinodépendant. at <http://www.inserm.fr/espace-journalistes/le-medicament-en-premiere-ligne-dans-le- traitement-du-diabete-de-type-2-devoile-ses-secrets-de-fonctionnement> 131. ameli.fr -Convention nationale des pharmaciens titulaires d'officine ,